Kardiologie KarMa s.r.o.
- Address
- Pulecny 184, 468 02 Pulecny, Czechia
Cardiovascular Diseases at Kardiologie KarMa s.r.o.
This site is focused on cardiovascular research, with clinical studies centered on atrial fibrillation and the prevention of cardioembolic events. The trials are designed to assess whether new treatment options can improve protection against stroke and other serious clot-related complications.
- Evaluating a new therapy for atrial fibrillation to reduce the risk of stroke and systemic embolism
- Studying treatment strategies aimed at better prevention of cardioembolic complications
The research at this Czechia-based clinic reflects a clear interest in improving how heart rhythm disorders are managed in everyday care.
Heart Failure Research
Another key area at this site is heart failure, where trials are exploring whether new treatment combinations can improve outcomes for people with persistent symptoms and reduced heart function. The main goal is to test whether these approaches can lower the risk of cardiovascular death and worsening heart failure events.
- Assessing a combination treatment for heart failure in patients with mildly to moderately reduced or preserved heart function
- Measuring whether the study treatment can reduce hospitalization and urgent care needs related to heart failure
These studies show an emphasis on finding better ways to support patients living with chronic heart disease and preventing clinical deterioration.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 634 other sites in Czechia
Therapeutic Area Benchmark — Czechia
Select a therapeutic area to compare against other sites in Czechia.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Czechia
Market Share
Country: Czechia
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Kardiologie KarMa s.r.o.
lock Showing 1 of 2 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active-Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation | Janssen Cilag International | Phase III | Not Recruiting | Aug 2023 | — |
IMP list
lock Showing 1 of 5 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Andexanet Alfa | 1 | Unknown | 2023-08-23 | 2023-08-23 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.